GEORGE RICHARD UHL, MD PHD
Neurology at Eastern Ave, Baltimore, MD

6362160, Mar 26, 2002

Jun 30, 1993

08/082848

Ted M. Dawson - Baltimore MD
Joseph P. Steiner - Hampstead MD
Valina L. Dawson - Baltimore MD
George R. Uhl - Towson MD
Solomon H. Snyder - Baltimore MD

The Johns Hopkins University School of Medicine - Baltimore MD

A61K 3800

514 2, 514 8, 514 12, 514 31, 514 27

Immunophilin-binding agents inhibit the phosphatase calcineurin, leading to the increased phosphorylation of certain brain proteins, including nitric oxide synthase. The increased levels of phosphorylation of nitric oxide synthase inhibits the enzymatic production of nitric oxide. Thus the neurotoxic effects of glutamate, which are ordinarily the result of vascular strokes and other neurodegenerative diseases, are minimized, because the neurotoxic effects are at least partially mediated by nitric oxide. Thus immunophilin-binding drugs can be used therapeutically in the treatment of vascular stroke and neurodegenerative disorders such as Alzheimers disease and Huntingtons disease.

6258556, Jul 10, 2001

Jan 28, 1994

8/188275

George Uhl - Towson MD
Peter Johnson - Perry Hall MD
Antonio M. Persico - Milan, IT
Jia Bei Wang - Baltimore MD

The United States of America as represented by the Department of Health and
Human Services - Washington DC

C12P 2106, C07H 2104, C07K 100, C12N 120

435 691

A human. mu. opiate receptor cDNA has been identified from a cerebral cortical CDNA library using sequences from the rat. mu. opiate receptor CDNA. The human. mu. opiate receptor (h. mu. OR1) shares 95% amino acid identity with the rat sequence. The expressed. mu. OR1 recognizes tested opiate drugs and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat. mu. opiate receptor. Effects on cyclic AMP are similar to those noted for the rat. mu. opiate receptor. Overlapping genomic clones spanning 50 kilobasepairs and hybridizing with the h. mu. OR1 cDNA contains exon sequences encoding the entire open reading frame of the human A opiate receptor are described. Analysis of hybridization to DNA prepared from human rodent hybrid cell lines and chromosomal in situ hybridization studies indicate localization to 6q24-25. An MspI polymorphism, producing a 3.

2011029, Dec 1, 2011

Feb 20, 2009

12/918940

Jed E. Rose - Durham NC, US
George R. Uhl - Towson MD, US

Duke University - Durham NC

C40B 30/04, C12Q 1/68, C07H 21/04

506 9, 536 231, 435 611

The present invention relates to genetic polymorphisms that are associated with dependence on an addictive substance. In particular, the present invention relates to a method for predicting success in addictive substance cessation in a subject, such as predicting success in nicotine cessation. In some embodiments, nicotine cessation is accompanied by a nicotine replacement source and/or an antidepressant. The invention further provides a method for identifying a subject who has an increased risk of becoming dependent on an addictive substance. In some embodiments, the addictive substance is nicotine. Also provided are isolated nucleic acid molecules containing the polymorphisms and reagents for detecting the polymorphic nucleic acid molecules.

5756307, May 26, 1998

Sep 7, 1994

8/301722

George R. Uhl - Towson MD
David Vandenbergh - Baltimore MD

The United States of America as represented by the Department of Health
and Human Services - Washington DC

C12N 1512, C12N 510

435 691

The cloning and characterization of a human dopamine transporter (HUDAT) cDNA is described. RFLP analysis is used to determine the distribution of HUDAT alleles in two ethic backgrounds. The means by which the association between HUDAT alleles and behavioral disorders which have altered HUDAT expression as a basis for their etiology is discussed. Methods for evaluating the expression of HUDAT are described.

5312734, May 17, 1994

Sep 20, 1991

7/762132

George R. Uhl - Towson MD
Michael J. Kuhar - Baltimore MD
Shoichi Shimada - Baltimore MD
Shigeo Kitayama - Baltimore MD
Amrat Patel - Baltimore MD
Chien-Liang Lin - Baltimore MD

The United States of America as represented by the Department of Health
and Human Services - Washington DC

C12P 2106, C12N 500, C12N 1500, C07H 1512

435 691

The invention described in this disclosure relates to a cloned cDNA encoding the dopamine transporter protein usually found in certain neural cells. The invention is further directed to the purified dopamine transporter protein and its use as a biosensor material and immunogen for the production of anti-DAT1 antibodies. The disclosure also discusses methods for use of the cDNA for diagnostic and treatment applications, and methods for use of permanent cell lines transformed with the dopamine transporter cDNA for pharmaceutical screening. The use of anti-DAT1 antibodies as a diagnostic tool is also addressed.

6225080, May 1, 2001

Apr 28, 1995

8/430286

George R. Uhl - Towson MD
C. Mark Eppler - Langehorne PA

C12P 2106, C12P 2104, C07H 2104, C12N 120

435 691

Isolated DNA encoding mu-subtype opioid receptor polypeptides is provided. Recombinant cloning vectors which include this DNA and cells that incorporate these vectors are also provided. Methods for producing these receptors and purifying them from native and heterologous sources are also disclosed.